Heart-Kidney hope: new drug trial for High-Risk patients
NCT ID NCT07029503
First seen Jan 28, 2026 · Last updated Jun 22, 2026 · Updated 22 times
Summary
This pilot study tests whether the drug eplerenone is safe and feasible for people with both heart failure (reduced pumping ability) and severe chronic kidney disease. Previous studies excluded such patients due to risks like high potassium. The trial will enroll 40 participants and monitor safety closely, with a plan to manage any problems. If successful, it could pave the way for better treatment in this underserved group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Cardiology, Danderyd Hospital, Karolinska Institutet
RECRUITINGStockholm, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
eplerenone (Inspra), a drug that helps the heart and kidneys by blocking a hormone that can cause fluid buildup and potassium problems
What this could lead to
If this trial succeeds, it could show that eplerenone is safe and helpful for heart failure patients with severe kidney disease, leading to better treatment options for this high-risk group.
What could go wrong
This is a small, early pilot trial with only 40 participants, so results may not apply to everyone. There are known risks of high potassium levels, worsening kidney function, and low blood pressure.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.